The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - The Aprepitant Protocol 052 Study Group

Paul J. Hesketh, Steven M. Grunberg, Richard J. Gralla, David G. Warr, Fausto Roila, Ronald De Wit, Sant P. Chawla, Alexandra D. Carides, Juliana Ianus, Mary E. Elmer, Judith K. Evans, Klaus Beck, Scott Reines, Kevin J. Horgan

Research output: Contribution to journalArticlepeer-review

661 Scopus citations

Fingerprint

Dive into the research topics of 'The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - The Aprepitant Protocol 052 Study Group'. Together they form a unique fingerprint.

Medicine & Life Sciences